1 Day_1777011671128_85597701.png&w=48&q=75)
Source:
فبراير.كوم
New ADHD medications boost patient hope in Morocco
Morocco now has licenses to market three formulations of a medication containing the active ingredient "methylphenidate" for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), with or without hyperactivity. This development facilitates regular access to the treatment within pharmacies and healthcare institutions. It is a significant step, especially considering that patients previously relied on exceptional imports of these medications. However, its commercial launch depends on completing the determination of the public price. Nonetheless, challenges remain in accessing medications such as "Ritalin" and "Concerta" due to slow procedures, which affect treatment continuity and threaten the academic and professional performance of children and adults with ADHD.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)